Physician profile
David Gaston
NPI 1205818283
$7,410.67
in general payments reported to CMS, 2019-2025
27 companies · $965 in 2025
The $965 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $511 · 2021: $1,081 · 2022: $1,464 · 2023: $1,144 · 2024: $1,338 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,352 · Education: $94.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,352.40 |
| Education | $94.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,303.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $914.76 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $761.74 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $694.87 | 2019-2025 | |
| Lilly USA, LLC | $567.25 | 2019-2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $487.31 | 2019-2025 | Ilumya |
| Mallinckrodt Hospital Products INC. | $430.98 | 2024-2025 | Acthar |
| Amgen INC. | $379.55 | 2019-2023 | Otezla |
| Janssen Biotech, INC. | $176.24 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Dusa Pharmaceuticals, INC. | $100.09 | 2019 | |
| Almirall LLC | $78.45 | 2022-2025 | Seysara, Klisyri |
| Genentech USA, INC. | $65.01 | 2019-2022 | |
| Organogenesis INC. | $63.11 | 2021-2023 | Puraply |
| Leo Pharma INC. | $46.89 | 2019-2023 | Adbry |
| Ucb, INC. | $42.01 | 2019-2025 | Bimzelx |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $37.71 | 2020-2021 | |
| Galderma Laboratories, L.P. | $34.19 | 2021-2025 | Nemluvio |
| Fresenius Kabi USA, LLC | $34.14 | 2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $34.10 | 2024-2025 | Sotyktu |
| Kerecis Limited | $27.66 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Kyowa Kirin, INC. | $27.15 | 2020 | |
| Celgene Corporation | $24.89 | 2019 | |
| Bioventus LLC | $23.02 | 2022 | |
| Incyte Corporation | $17.39 | 2022 | |
| Verrica Pharmaceuticals INC. | $13.81 | 2023 | Ycanth |
| Mayne Pharma Commercial LLC | $13.06 | 2019 | |
| Strata Skin Sciences, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gaston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.